 So how many patients does this affect? And then also vulnerability. The MAPS bill would help us assess potentially the exposure of where the drugs come from instead of assess the vulnerability. And using this kind of a framework, we can then start thinking about where the government would need to invest. Again, economics is driving us outside of the United States. We would have to reverse the economics if we want to reverse these trends.